Download Citation
Article Source:
ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy
Aceves-Luquero CI,
Agarwal A,
Callejas-Valera JL,
Arias-González L,
Esparís-Ogando A,
et al.
(2009)
ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy.
PLOS ONE 4(7): e6124.
https://doi.org/10.1371/journal.pone.0006124